MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
20 Febbraio 2024 - 12:00PM
MannKind Corporation (Nasdaq: MNKD) will release
its 2023 fourth quarter and full year financial results and its
management will host a conference call to discuss these results and
corporate updates at 5:00 PM (Eastern Time) on Tuesday, February
27, 2024.
Presenting from the Company will be its Chief Executive Officer,
Michael Castagna, and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via
the Internet may do so by visiting the Company's website at
https://investors.mannkindcorp.com/events-and-presentations under
Events & Presentations.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
innovative therapeutic products and devices to address serious
unmet medical needs for those living with endocrine and orphan lung
diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us
on LinkedIn, Facebook, Twitter or Instagram.
For MannKind: Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
Grafico Azioni MannKind (NASDAQ:MNKD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni MannKind (NASDAQ:MNKD)
Storico
Da Set 2023 a Set 2024